Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia.

Diabetologia - 1 Jan 2014

Stride Amanda, Shields Beverley, Gill-Carey Olivia, Chakera Ali J, Colclough Kevin, Ellard Sian, Hattersley Andrew T

Abstract excerpt

AIMS/HYPOTHESIS: Heterozygous glucokinase (GCK) mutations cause mild, fasting hyperglycaemia from birth. Although patients are usually asymptomatic and have glycaemia within target ranges, some are put on pharmacological treatment. We aimed to investigate how many patients are on pharmacological treatment and the impact of treatment on glycaemic control. METHODS: Treatment details were ascertained for 799...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Body Mass Index

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucokinase

Share to Glycated Hemoglobin

Share to Hyperglycemia

Share to Hypoglycemic Agents

Share to Insulin

Share to Longitudinal Studies

Source

Open in PubMed Open full text

Identifiers

PMID: 24092492
DOI: 10.1007/s00125-013-3075-x
PMCID: PMC3855531

Genes

GCK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia.PMID 24092492Read ↗

Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies.Semantic proximity Read ↗

Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation.Semantic proximity Read ↗

14-fold increased prevalence of rare glucokinase gene variant carriers in unselected Danish patients with newly diagnosed type 2 diabetes.Semantic proximity Read ↗

A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metforminSemantic proximity Read ↗

GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated.Semantic proximity Read ↗

Diagnosis and management of glucokinase monogenic diabetes in pregnancy: current perspectivesSemantic proximity Read ↗

Phenotype, genotype and glycaemic variability in people with activating mutations in the ABCC 8 gene: response to appropriate therapySemantic proximity Read ↗

A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria.Semantic proximity Read ↗

HbA1c-based diabetes diagnosis among patients with glucokinase mutation (GCK-MODY) is affected by a genetic variant of glucose-6-phosphatase (G6PC2).Semantic proximity Read ↗

Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia.Semantic proximity Read ↗

Functional Characterization of Glucokinase Variants to Aid Clinical Interpretation of Monogenic Diabetes.Semantic proximity Read ↗

[Fasting hyperglycaemia and polymorphism in glucokinase promoter (rs1799884)].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.